At Ares Genetics, we develop precision diagnostics for precision medicine to improve the way infections are diagnosed and treated.
We are data scientists, bioinformaticians, microbiologists, pharmaceutical, diagnostic and commercial experts that share a vision for the next-generation of genomics-based infectious disease diagnostics & therapeutics.
Join us in taking infectious disease diagnostics to the next level!
Besides the openings listed below, we are regularly offering part- or full-time positions as well as PhD and master theses and welcome unsolicitated applications.
At Ares, we pursue a partnership based, open-innovation approach with academic and industry partners and are committed to sharing our developments with the community.
Joint publication with Prof. Keller’s group at Saarland University assessing the heterogeneity of in silico plasmid predictions based on whole-genome-sequenced clinical isolates. The study identified a high degree of heterogeneity and variation in sensitivity and precision for plasmid identification across taxa and computational approaches. Nevertheless, existing open source tools are very valuable for investigating the plasmid-borne resistome. Building upon the peer-reviewed research findings, the proprietary ARES Technology allows for fast and optimized plasmid identification from whole-genome sequencing data.
Joint publication with Prof. Keller's Group Keller’s group at Saarland University introducing GEAR-base as a standardized research resource for antibiotic resistance genotypes and phenotypes. GEAR-base builds on Ares’ proprietary collection of pathogen genomes and resistance profiles and we invite you to join us to further advance antibiotic resistance research. Please sign up at https://gear-base.com or contact us at firstname.lastname@example.org and you will receive an invitation to join GEAR-base for academic research use upon publication of the accompanying manuscript (currently under review).
We offer a comprehensive portfolio of solutions for antimicrobial drug discovery, clinical development, and product lifecycle management. Our solutions aim at supporting data-driven target and lead prioritization, accelerating clinical trials, augmenting clinical data for regulatory submissions, and informed antimicrobial drug use for effective antibiotic stewardship post launch.
Joint publication with Prof. Keller’s group at Saarland University comparing genome versus proteome-based identification of clinical bacterial isolates. Key findings include that taxonomic identification based on the proteome (by mass spectrometry, MS-biotyping) and the genome (by next-generation sequencing, NGS) show high concordance for clinical application. While NGS successfully resolved all clinical isolates on the species level, for 12% of the cases MS-biotyping resulted in genus level classification only. Building upon the peer-reviewed research findings, ARES Technology allows for fast and accurate taxonomic identification on the species level.